SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-025450
Filing Date
2022-07-07
Accepted
2022-07-07 16:17:14
Documents
70
Period of Report
2022-05-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-10q_20220531.htm   iXBRL 10-Q 3067778
2 EX-31.1 nrix-ex311_6.htm EX-31.1 21837
3 EX-31.2 nrix-ex312_8.htm EX-31.2 21773
4 EX-32.1 nrix-ex321_9.htm EX-32.1 12865
  Complete submission text file 0001564590-22-025450.txt   9647835

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nrix-20220531.xsd EX-101.SCH 49818
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nrix-20220531_cal.xml EX-101.CAL 50163
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrix-20220531_def.xml EX-101.DEF 155572
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20220531_lab.xml EX-101.LAB 401472
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20220531_pre.xml EX-101.PRE 304056
64 EXTRACTED XBRL INSTANCE DOCUMENT nrix-10q_20220531_htm.xml XML 1857716
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 221071836
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences